Bio News

Polpharma Biologics has entered into an exclusive licensing agreement with Argentina-based Tuteur for one autoimmune disease biosimilar, marking its entry into the Latin American market. Under the agreement, Polpharma will be responsible for development and manufacturing, while Tuteur will handle commercialization and distribution in Latin America, excluding Brazil. The biosimilar is expected to have its regulatory application submitted within the next 3 years.

BIOBOOK TEAM
biobookmedia@biobook.co.krCG Oncology: Cretostimogene Cuts Bladder Cancer Recurrence Risk by 68%; FDA Filing to Expand
CG Oncology: 68% Lower Risk of Bladder Cancer Recurrence; Shares Surge 12%
U.S. FDA Rejects Summit and Akeso’s PD-1/VEGF Lung Cancer Drug
Biogen Signs $411 Million Deal With Trimtech for Neurodegenerative Diseases
AstraZeneca’s new myasthenia gravis drug cligepa approved in the U.S. and EU
Helus meets primary endpoint in phase 3 trial of depression drug candidate, with 7.6-point improvement over placebo